The offering provides a substantial cash runway to fund pivotal trials for ERAS-0015 through key catalysts in 2027, including a potential registration-enabling NSCLC trial and Phase 3 PDAC trial. The 10% dilution is a near-term headwind, but the strong Phase 1 data and accelerated development plans could support the stock if data continues to impress. Monitor for further clinical updates and any insider selling post-lockup expiration (60 days).
Price Chart
Executive Summary
Erasca is conducting a $550M follow-on offering of 31.4M shares at $17.50 (2.2% discount to last sale), with net proceeds of ~$516M to fund R&D for its RAS/MAPK pipeline. The filing also discloses encouraging updated Phase 1 data for lead candidate ERAS-0015, showing a 57% uORR8wk in 2L KRAS G12X PDAC at the 32mg RDE dose. The combination of dilutive financing and positive clinical data creates a mixed signal for the stock.
Key Facts
- Offering of 31,428,572 shares at $17.50 per share, raising $550M in gross proceeds (~$516M net)
- Underwriters have a 30-day option to purchase an additional 4,714,285 shares
- Post-offering shares outstanding: 342,235,460 (or 346,949,745 if overallotment exercised)
- New investors face immediate dilution of $14.84 per share (85% of offering price)
- Net tangible book value increases from $1.27 to $2.66 per share post-offering
- Updated Phase 1 data for ERAS-0015 shows 57% uORR8wk (N=7) at 32mg QD in 2L KRAS G12X PDAC
- ERAS-0015 combination with panitumumab cleared first dose escalation cohort with no DLTs
- Company plans to initiate potentially registration-enabling trial in NSCLC in H1 2027 and Phase 3 pivotal trial in PDAC in 2027
- Proceeds to fund R&D, working capital, and potential in-licensing/acquisitions
- $200M ATM facility with Jefferies remains available
Financial Impact
Gross proceeds of $550M ($516M net) from sale of 31.4M shares at $17.50; immediate dilution of $14.84 per share for new investors; post-offering cash position increases to ~$909.5M in net tangible book value
Risk Factors
- Immediate and substantial dilution of 85% of offering price for new investors
- Clinical-stage biotech with no approved products; ERAS-0015 data is preliminary and from small sample sizes
- Potential for further dilution from $200M ATM facility and outstanding options (58.4M shares)
- Competitive landscape for RAS/MAPK-targeted therapies is intense
- One Grade 5 pneumonitis event reported in safety data raises toxicity concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-303352 |
| Document: d116467dexfilingfees.htm | 0001193125-26-303352 |
| Document: 0001193125-26-303352-index-headers.html | 0001193125-26-303352 |
| Document: 0001193125-26-303352-index.html | 0001193125-26-303352 |
| Document: 0001193125-26-303352.txt | 0001193125-26-303352 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access